BACKGROUND AND OBJECTIVES: This study examined differences in the concentration of markers of mineral metabolism across race in patients with advanced CKD not requiring dialysis and ESRD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Concentrations of 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF-23) were measured in stored plasma samples of 1497 patients with advanced CKD not yet on dialysis and ESRD who participated in the Homocysteine in Kidney and End Stage Renal Disease study. Linear regression models were used to examine the relationship between race and 25(OH)D, 1,25(OH)(2)D, iPTH, and FGF-23 concentrations. RESULTS: Non-Hispanic white patients comprised 58% of the cohort, whereas non-Hispanic blacks comprised 42%. Median (interquartile range) FGF-23concentrations were lower in blacks compared with whites with CKD (323 [181-655] versus 431 [232-1026] RU/ml; P<0.001) but not in ESRD. In adjusted linear regression models, blacks with CKD not requiring dialysis had significantly lower plasma FGF-23 concentrations (difference, -159; 95% confidence interval, -205 to -106; P<0.001) compared with whites, independent of plasma 25(OH)D, 1,25(OH)(2)D, and iPTH concentrations. This difference was not observed in the ESRD group. The magnitude of correlation for the relationships between 1,25(OH)(2)D with iPTH, FGF-23 with 1,25(OH)(2)D, and FGF-23 with iPTH were stronger among blacks than whites with CKD not requiring dialysis. CONCLUSIONS: In advanced CKD not requiring dialysis, blacks have lower FGF-23 concentrations than whites. Blacks with CKD and ESRD have lower 25(OH)D and higher iPTH compared with whites, independent of FGF-23 concentrations.
RCT Entities:
BACKGROUND AND OBJECTIVES: This study examined differences in the concentration of markers of mineral metabolism across race in patients with advanced CKD not requiring dialysis and ESRD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Concentrations of 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)(2)D), intact parathyroid hormone (iPTH), and fibroblast growth factor 23 (FGF-23) were measured in stored plasma samples of 1497 patients with advanced CKD not yet on dialysis and ESRD who participated in the Homocysteine in Kidney and End Stage Renal Disease study. Linear regression models were used to examine the relationship between race and 25(OH)D, 1,25(OH)(2)D, iPTH, and FGF-23 concentrations. RESULTS: Non-Hispanic white patients comprised 58% of the cohort, whereas non-Hispanic blacks comprised 42%. Median (interquartile range) FGF-23 concentrations were lower in blacks compared with whites with CKD (323 [181-655] versus 431 [232-1026] RU/ml; P<0.001) but not in ESRD. In adjusted linear regression models, blacks with CKD not requiring dialysis had significantly lower plasma FGF-23 concentrations (difference, -159; 95% confidence interval, -205 to -106; P<0.001) compared with whites, independent of plasma 25(OH)D, 1,25(OH)(2)D, and iPTH concentrations. This difference was not observed in the ESRD group. The magnitude of correlation for the relationships between 1,25(OH)(2)D with iPTH, FGF-23 with 1,25(OH)(2)D, and FGF-23 with iPTH were stronger among blacks than whites with CKD not requiring dialysis. CONCLUSIONS: In advanced CKD not requiring dialysis, blacks have lower FGF-23 concentrations than whites. Blacks with CKD and ESRD have lower 25(OH)D and higher iPTH compared with whites, independent of FGF-23 concentrations.
Authors: Ming Teng; Myles Wolf; M Norma Ofsthun; J Michael Lazarus; Miguel A Hernán; Carlos A Camargo; Ravi Thadhani Journal: J Am Soc Nephrol Date: 2005-02-23 Impact factor: 10.121
Authors: Bruce M Robinson; Marshall M Joffe; Ronald L Pisoni; Friedrich K Port; Harold I Feldman Journal: J Am Soc Nephrol Date: 2006-09-20 Impact factor: 10.121
Authors: Cassianne Robinson-Cohen; Michael Shlipak; Mark Sarnak; Ronit Katz; Carmen Peralta; Bessie Young; Andrew N Hoofnagle; Moyses Szklo; Joachim H Ix; Bruce M Psaty; Ian H de Boer; Bryan Kestenbaum; Nisha Bansal Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958
Authors: Keith C Norris; Sandra F Williams; Connie M Rhee; Susanne B Nicholas; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; L Ebony Boulware Journal: Semin Dial Date: 2017-03-09 Impact factor: 3.455
Authors: Rupal Mehta; Xuan Cai; Alexander Hodakowski; Bharat Thyagarajan; Donglin Zeng; Phyllis C Zee; William K Wohlgemuth; Susan Redline; James P Lash; Myles Wolf; Tamara Isakova Journal: Bone Date: 2018-07-03 Impact factor: 4.398
Authors: Marciana L Laster; Bryce Rowan; Hua-Chang Chen; Tae-Hwi Schwantes-An; Xin Sheng; Peter A Friedman; T Alp Ikizler; Janet S Sinshiemer; Joachim H Ix; Katalin Susztak; Ian H de Boer; Bryan Kestenbaum; Adriana Hung; Sharon M Moe; Farzana Perwad; Cassianne Robinson-Cohen Journal: J Clin Endocrinol Metab Date: 2022-08-18 Impact factor: 6.134
Authors: Julia J Scialla; Rulan S Parekh; Joseph A Eustace; Brad C Astor; Laura Plantinga; Bernard G Jaar; Tariq Shafi; Josef Coresh; Neil R Powe; Michal L Melamed Journal: Am J Nephrol Date: 2015-08-20 Impact factor: 3.754
Authors: D L White; S Tavakoli-Tabasi; F Kanwal; D J Ramsey; A Hashmi; J Kuzniarek; P Patel; J Francis; H B El-Serag Journal: Aliment Pharmacol Ther Date: 2013-05-26 Impact factor: 8.171
Authors: Janet M Chiang; George A Kaysen; Anne L Schafer; Cynthia Delgado; Kirsten L Johansen Journal: J Ren Nutr Date: 2018-03-29 Impact factor: 3.655